(Q34386229)

1 August 2017

title

alpha-Interferon treatment of patients with chronic fatigue syndrome (English)

1 reference

1 August 2017

D M See

1

1 reference

1 August 2017

J G Tilles

series ordinal

2

1 reference

1 August 2017

publication date

1 January 1996

1 reference

Immunological Investigations

1 August 2017

published in

1 reference

1 August 2017

volume

25

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

153-164

1 reference

A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Chronic fatigue syndrome: a working case definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

IgG subclass deficiencies in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Increased (2'-5')-oligo-A synthetase activity in patients with prolonged illness associated with serological evidence of persistent Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Immune function in chronic active Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Lymphocyte phenotype and function in the chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

A chronic "postinfectious" fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Interferon-alpha in malignant and viral diseases. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

A Comprehensive Immunological Analysis in Chronic Fatigue Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Studies on enterovirus in patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Infection of natural killer cells by human herpesvirus 6

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

Biology of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820139609059298

10.3109/08820139609059298

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference